

Ervin Steve Woodle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9230753/publications.pdf>

Version: 2024-02-01

194
papers

10,847
citations

28274

55
h-index

37204

96
g-index

202
all docs

202
docs citations

202
times ranked

8420
citing authors

#	ARTICLE	IF	CITATIONS
1	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	14.5	501
2	EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS. <i>Transplantation</i> , 1999, 68, 1517-1525.	1.0	489
3	Malignancy after Transplantation. <i>Transplantation</i> , 2005, 80, S254-S264.	1.0	482
4	A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Surgery, 2008, 248, 564-577.	4.2	420
5	Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. <i>Transplantation</i> , 2008, 86, 1754-1761.	1.0	362
6	Alemtuzumab Induction in Renal Transplantation. <i>New England Journal of Medicine</i> , 2011, 364, 1909-1919.	27.0	360
7	POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1996, 62, 370-375.	1.0	272
8	Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss. <i>American Journal of Transplantation</i> , 2009, 9, 1063-1071.	4.7	199
9	Ethics of a Paired-Kidney-Exchange Program. <i>New England Journal of Medicine</i> , 1997, 336, 1752-1755.	27.0	185
10	Complications in 100 Living-Liver Donors. <i>Annals of Surgery</i> , 1998, 228, 214-219.	4.2	176
11	De Novo Cancers Arising in Organ Transplant Recipients are Associated With Adverse Outcomes Compared With the General Population. <i>Transplantation</i> , 2009, 87, 1347-1359.	1.0	173
12	PHASE I TRIAL OF A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 ANTIBODY, huOKT3??1 (Ala-Ala) IN THE TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION. <i>Transplantation</i> , 1999, 68, 608-616.	1.0	170
13	Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection. <i>Transplantation</i> , 2010, 89, 277-284.	1.0	166
14	PORTAL VEIN THROMBOSIS AND STENOSIS IN PEDIATRIC LIVER TRANSPLANTATION1. <i>Transplantation</i> , 1996, 62, 748-754.	1.0	150
15	Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition. <i>Transplantation</i> , 2011, 91, 1218-1226.	1.0	139
16	A MULTICENTER TRIAL OF FK506 (TACROLIMUS) THERAPY IN REFRACTORY ACUTE RENAL ALLOGRAFT REJECTION. <i>Transplantation</i> , 1996, 62, 594-599.	1.0	134
17	An initial experience and evolution of laparoscopic hepatic resectional surgery. <i>Surgery</i> , 2004, 136, 804-811.	1.9	131
18	Interplay of Cellular and Humoral Immune Responses against BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy. <i>Journal of Virology</i> , 2006, 80, 3495-3505.	3.4	129

#	ARTICLE	IF	CITATIONS
19	Prospective Iterative Trial of Proteasome Inhibitor-Based Desensitization. American Journal of Transplantation, 2015, 15, 101-118.	4.7	127
20	Primary Living-Donor Liver Transplantation at the University of Chicago. Annals of Surgery, 2000, 232, 104-111.	4.2	122
21	Are Concerns Over Right Laparoscopic Donor Nephrectomy Unwarranted?. Annals of Surgery, 2001, 233, 645-651.	4.2	110
22	Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on cd3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation, 2002, 73, 1514-1518.	1.0	106
23	Analysis of Factors that Influence Survival with Post-Transplant Lymphoproliferative Disorder in Renal Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience. American Journal of Transplantation, 2005, 5, 775-780.	4.7	95
24	Donors with central nervous system malignancies: are they truly safe?. Transplantation, 2003, 76, 340-343.	1.0	92
25	Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney International, 2012, 81, 1067-1074.	5.2	92
26	The Relationship of Untreated Borderline Infiltrates by the Banff Criteria to Acute Rejection in Renal Allograft Biopsies. Journal of the American Society of Nephrology: JASN, 1999, 10, 1806-1814.	6.1	91
27	Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant Patients. Transplantation, 2012, 93, 319-324.	1.0	90
28	Malignant Melanoma in Solid Transplant Recipients. Archives of Dermatology, 2011, 147, 790.	1.4	89
29	ETHICAL ISSUES IN INCREASING LIVING KIDNEY DONATIONS BY EXPANDING KIDNEY PAIRED EXCHANGE PROGRAMS. Transplantation, 2000, 69, 1539-1543.	1.0	89
30	INCIDENCE AND OUTCOME OF INFECTION BY VANCOMYCIN-RESISTANT ENTEROCOCCUS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 65, 439-442.	1.0	88
31	Gastric Bypass in Morbidly Obese Patients with Chronic Renal Failure and Kidney Transplant. Transplantation, 2004, 78, 469-474.	1.0	87
32	A Multicenter Pilot Study of Early (4-Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus. American Journal of Transplantation, 2005, 5, 157-166.	4.7	86
33	Proteasome inhibition for antibody-mediated rejection. Current Opinion in Organ Transplantation, 2009, 14, 662-666.	1.6	86
34	PRIMUM NON NOCERE: AVOIDING HARM TO VULNERABLE WAIT LIST CANDIDATES IN AN INDIRECT KIDNEY EXCHANGE. Transplantation, 2001, 72, 648-654.	1.0	84
35	A Comparison of Tacrolimus and Cyclosporine in Liver Transplantation: Effects on Renal Function and Cardiovascular Risk Status. American Journal of Transplantation, 2005, 5, 1111-1119.	4.7	83
36	Laparoscopic liver resection. Journal of the American College of Surgeons, 2005, 200, 472-480.	0.5	82

#	ARTICLE	IF	CITATIONS
37	COMPARISON OF PANCREAS TRANSPLANTATION WITH PORTAL VENOUS AND ENTERIC EXOCRINE DRAINAGE TO THE STANDARD TECHNIQUE UTILIZING BLADDER DRAINAGE OF EXOCRINE SECRETIONS. <i>Transplantation</i> , 1996, 62, 1353-1356.	1.0	81
38	Assessment of tacrolimus inpatient variability in stable adherent transplant recipients: Establishing baseline values. <i>American Journal of Transplantation</i> , 2019, 19, 1410-1420.	4.7	79
39	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	8.4	76
40	West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death ¹ . <i>Transplantation</i> , 2004, 77, 466-469.	1.0	73
41	Laparoscopic donor nephrectomy vs. open live donor nephrectomy: a quality of life and functional study. <i>Clinical Transplantation</i> , 2005, 19, 102-109.	1.6	70
42	A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin [®] in living donor kidney transplantation. <i>Clinical Transplantation</i> , 2010, 24, 73-83.	1.6	69
43	Association Between Donor-Specific Antibodies and Acute Rejection and Resolution in Small Bowel and Multivisceral Transplantation. <i>Transplantation</i> , 2011, 92, 709-715.	1.0	68
44	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	4.7	67
45	LIVER TRANSPLANTATION IN THE FIRST THREE MONTHS OF LIFE. <i>Transplantation</i> , 1998, 66, 606-609.	1.0	67
46	Impact of recipient morbid obesity on outcomes after liver transplantation. <i>Transplant International</i> , 2015, 28, 148-155.	1.6	66
47	Right donor nephrectomy: A comparison of hand-assisted transperitoneal and retroperitoneal laparoscopic approaches. <i>Transplantation</i> , 2004, 77, 521-525.	1.0	64
48	Neighborhood Level Effects of Socioeconomic Status on Liver Transplant Selection and Recipient Survival. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1934-1941.	4.4	64
49	Donor Kidneys With Small Renal Cell Cancers: Can They Be Transplanted?. <i>Transplantation Proceedings</i> , 2005, 37, 581-582.	0.6	63
50	Desensitization in kidney transplantation: review and future perspectives. <i>Clinical Transplantation</i> , 2014, 28, 494-507.	1.6	63
51	Multivariate Analysis of Risk Factors for Acute Rejection in Early Corticosteroid Cessation Regimens Under Modern Immunosuppression. <i>American Journal of Transplantation</i> , 2005, 5, 2740-2744.	4.7	62
52	Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis. <i>Hpb</i> , 2014, 16, 1088-1094.	0.3	62
53	Telemedicine Based Remote Home Monitoring After Liver Transplantation. <i>Annals of Surgery</i> , 2019, 270, 564-572.	4.2	59
54	Hand-Assisted Laparoscopic Living-Donor Nephrectomy as an Alternative to Traditional Laparoscopic Living-Donor Nephrectomy. <i>American Journal of Transplantation</i> , 2002, 2, 983-988.	4.7	58

#	ARTICLE	IF	CITATIONS
55	Experience with 274 Cardiac Transplant Recipients with Posttransplant Lymphoproliferative Disorder: A Report from the Israel Penn International Transplant Tumor Registry. <i>Transplantation</i> , 2004, 78, 1676-1682.	1.0	58
56	Characteristics and Survival Patterns of Solid Organ Transplant Patients Developing De Novo Colon and Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 1898-1903.	1.3	57
57	Consequences of vancomycin-resistant <i>Enterococcus</i> in liver transplant recipients: a matched control study. <i>Clinical Transplantation</i> , 2005, 19, 050824032258001.	1.6	56
58	Skin Cancer Following Transplantation: The Israel Penn International Transplant Tumor Registry Experience. <i>Transplantation Proceedings</i> , 2005, 37, 962-963.	0.6	56
59	Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012. <i>Liver Transplantation</i> , 2014, 20, 1347-1355.	2.4	56
60	PROGRAMMED CELL DEATH. <i>Transplantation</i> , 1998, 66, 681-691.	1.0	56
61	Malignancy in pediatric transplant recipients. <i>Seminars in Pediatric Surgery</i> , 2006, 15, 179-187.	1.1	55
62	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	6.1	55
63	Chemotherapy for Posttransplant Lymphoproliferative Disorder: The Israel Penn International Transplant Tumor Registry Experience. <i>Transplantation Proceedings</i> , 2005, 37, 956-957.	0.6	54
64	Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy. <i>American Journal of Transplantation</i> , 2020, 20, 422-429.	4.7	54
65	Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1670-1677.	4.5	53
66	Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. <i>Transplantation</i> , 2002, 73, 1166-1169.	1.0	50
67	Ethical Considerations for Participation of Nondirected Living Donors in Kidney Exchange Programs. <i>American Journal of Transplantation</i> , 2010, 10, 1460-1467.	4.7	50
68	LONG-TERM OUTCOME OF KIDNEY-PANCREAS TRANSPLANT RECIPIENTS WITH GOOD GRAFT FUNCTION AT ONE YEAR. <i>Transplantation</i> , 1996, 62, 451-456.	1.0	50
69	YPSL (rPSGL-1g) for improvement of early renal allograft function: a double-blind, placebo-controlled, multicenter Phase IIa study^{1,2,3}. <i>Clinical Transplantation</i> , 2011, 25, 523-533.	1.6	49
70	Clinical Implications of Donor Warm and Cold Ischemia Time in Donor After Circulatory Death Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1342-1352.	2.4	49
71	A prospective, iterative, adaptive trial of carfilzomib-based desensitization. <i>American Journal of Transplantation</i> , 2020, 20, 411-421.	4.7	47
72	Assessment of Efficacy and Safety of FK778 in Comparison With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy. <i>Transplantation</i> , 2010, 90, 891-897.	1.0	45

#	ARTICLE	IF	CITATIONS
73	Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation. Antioxidants and Redox Signaling, 2014, 21, 2401-2418.	5.4	45
74	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	4.7	45
75	Central Nervous System Tumors in Donors: Misdiagnosis Carries a High Morbidity and Mortality. Transplantation Proceedings, 2005, 37, 583-584.	0.6	44
76	FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrology Dialysis Transplantation, 2011, 26, 3802-3805.	0.7	44
77	Effect of pretransplant diabetes on short-term outcomes after liver transplantation: A National cohort study. Liver International, 2015, 35, 1902-1909.	3.9	44
78	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American Journal of Transplantation, 2019, 19, 3035-3045.	4.7	44
79	Orthotopic Liver Transplantation in a Patient With Amanita Poisoning. JAMA - Journal of the American Medical Association, 1985, 253, 69.	7.4	42
80	Risk Assessment of Immunosuppressive Therapy in Facial Transplantation. Plastic and Reconstructive Surgery, 2007, 120, 657-668.	1.4	42
81	Surgical techniques in right laparoscopic donor nephrectomy1 1No competing interests declared.. Journal of the American College of Surgeons, 2002, 195, 131-137.	0.5	41
82	Prostate Cancer Prior to Solid Organ Transplantation: The Israel Penn International Transplant Tumor Registry Experience. Transplantation Proceedings, 2005, 37, 958-959.	0.6	41
83	Monitoring of Inosine Monophosphate Dehydrogenase Activity as a Biomarker for Mycophenolic Acid Effect: Potential Clinical Implications. Therapeutic Drug Monitoring, 2007, 29, 141-149.	2.0	39
84	Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. American Journal of Transplantation, 2020, 20, 1039-1055.	4.7	39
85	Temporary silastic mesh closure for adult liver transplantation: A safe alternative for the difficult abdomen. Liver Transplantation, 2007, 13, 258-265.	2.4	38
86	Hospital utilization and consequences of readmissions after liver transplantation. Surgery, 2014, 156, 871-879.	1.9	38
87	Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	5.6	38
88	ACTIVATION OF HUMAN T CELLS IN VIVO FOLLOWING TREATMENT OF TRANSPLANT RECIPIENTS WITH OKT3. Transplantation, 1990, 50, 608-612.	1.0	37
89	BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. Journal of Clinical Virology, 2008, 42, 198-202.	3.1	37
90	Proteasome inhibitor treatment of antibody-mediated allograft rejection. Current Opinion in Organ Transplantation, 2011, 16, 434-438.	1.6	37

#	ARTICLE	IF	CITATIONS
91	Prospective Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy in Renal Transplant Candidates and Recipients. <i>Transplantation</i> , 2012, 94, 352-361.	1.0	37
92	USE OF POLYTETRAFLUOROETHYLENE PATCH FOR TEMPORARY WOUND CLOSURE AFTER PEDIATRIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1996, 62, 1034-1036.	1.0	36
93	Randomized Controlled Pilot Study of B Cell-Targeted Induction Therapy in HLA Sensitized Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 3142-3154.	4.7	35
94	TACROLIMUS THERAPY FOR REFRACTORY ACUTE RENAL ALLOGRAFT REJECTION. <i>Transplantation</i> , 1996, 62, 906-910.	1.0	35
95	OKT3 F(AB) ₂ FRAGMENTS RETENTION OF THE IMMUNOSUPPRESSIVE PROPERTIES OF WHOLE ANTIBODY WITH MARKED REDUCTION IN T CELL ACTIVATION AND LYMPHOKINE RELEASE. <i>Transplantation</i> , 1991, 52, 354-360.	1.0	34
96	Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 527-532.	2.0	34
97	Clinical Review of Nonalcoholic Steatohepatitis in Liver Surgery and Transplantation. <i>Journal of the American College of Surgeons</i> , 2010, 210, 515-526.	0.5	34
98	TACROLIMUS FOR PRIMARY TREATMENT OF STEROID-RESISTANT HEPATIC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1996, 61, 1365-1369.	1.0	33
99	African-American Renal Transplant Recipients Benefit from Early Corticosteroid Withdrawal Under Modern Immunosuppression. <i>American Journal of Transplantation</i> , 2005, 5, 356-365.	4.7	32
100	Proteasome inhibitor therapy for antibody-mediated rejection. <i>Pediatric Transplantation</i> , 2011, 15, 548-556.	1.0	32
101	Targeting the Ubiquitin-Proteasome System in Solid Tumors. <i>Seminars in Hematology</i> , 2012, 49, 277-283.	3.4	31
102	Impact of Induction Therapy on Circulating T Follicular Helper Cells and Subsequent Donor-Specific Antibody Formation After Kidney Transplant. <i>Kidney International Reports</i> , 2019, 4, 455-469.	0.8	31
103	A Prospective, Randomized, Multicenter, Double-Blind Study of Early Corticosteroid Cessation Versus Long-Term Maintenance of Corticosteroid Therapy With Tacrolimus and Mycophenolate Mofetil in Primary Renal Transplant Recipients: One Year Report. <i>Transplantation Proceedings</i> , 2005, 37, 804-808.	0.6	30
104	MALTOMA: A helicobacter pylori-associated malignancy in transplant patients. <i>Transplantation</i> , 2003, 75, 225-228.	1.0	29
105	Laparoscopic Living Donor Nephrectomy for Kidneys With Multiple Arteries. <i>Transplantation Proceedings</i> , 2005, 37, 629-630.	0.6	29
106	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. <i>PLoS Medicine</i> , 2017, 14, e1002428.	8.4	29
107	Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. <i>Virology</i> , 2010, 404, 312-318.	2.4	28
108	Laparoscopic Right Living Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2005, 37, 631-632.	0.6	26

#	ARTICLE	IF	CITATIONS
109	Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival. <i>Transplantation</i> , 2015, 99, 2167-2173.	1.0	26
110	Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. <i>American Journal of Kidney Diseases</i> , 2020, 75, 857-867.	1.9	26
111	The Influence of Immunomodulatory Diets on Transplant Success and Complications. <i>Transplantation</i> , 2005, 79, 460-465.	1.0	25
112	Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. <i>Transplant International</i> , 2006, 19, 295-302.	1.6	24
113	Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 2252-2261.	4.7	24
114	OKT3 THERAPY FOR HEPATIC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1991, 51, 1207-1212.	1.0	23
115	Independent effect of black recipient race on short-term outcomes after liver transplantation. <i>Surgery</i> , 2015, 157, 774-784.	1.9	23
116	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. <i>Clinical Transplantation</i> , 2017, 31, e12975.	1.6	23
117	Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients. <i>Annals of Internal Medicine</i> , 2018, 169, 214.	3.9	23
118	Maximizing renal artery length in right laparoscopic donor nephrectomy by retrocaval exposure of the aortorenal junction. <i>Transplantation</i> , 2003, 75, 83-85.	1.0	22
119	IN VIVO ADMINISTRATION OF ANTI-MURINE CD3 MONOCLONAL ANTIBODY INDUCES SELECTIVE, LONG-TERM ANERGY IN CD8+ T CELLS. <i>Transplantation</i> , 1996, 61, 798-803.	1.0	22
120	Posttransplant Malignancy. <i>Progress in Transplantation</i> , 2004, 14, 193-200.	0.7	21
121	How can donors with a previous malignancy be evaluated?. <i>Journal of Hepatology</i> , 2006, 45, 503-507.	3.7	21
122	Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation. <i>Surgery</i> , 2014, 156, 1049-1056.	1.9	21
123	Use of HCV Ab+/NAT-ve donors in HCV na-ve renal transplant recipients to expand the kidney donor pool. <i>Clinical Transplantation</i> , 2019, 33, e13598.	1.6	21
124	Polyomavirus nephropathy in kidney transplantation. <i>Progress in Transplantation</i> , 2004, 14, 130-142.	0.7	21
125	ANTI-CD3 MONOCLONAL ANTIBODY THERAPY. <i>Transplantation</i> , 1991, 52, 361-368.	1.0	20
126	Proteasome Inhibition for Antibody-Mediated Allograft Rejection. <i>Seminars in Hematology</i> , 2012, 49, 263-269.	3.4	20

#	ARTICLE	IF	CITATIONS
127	Hospital Resource Use with Donation after Cardiac Death Allografts in Liver Transplantation: A Matched Controlled Analysis from 2007 to 2011. <i>Journal of the American College of Surgeons</i> , 2015, 220, 951-958.	0.5	20
128	The Role of Immunosuppression in Lymphoma. <i>Recent Results in Cancer Research</i> , 2002, 159, 55-66.	1.8	20
129	Posttransplant malignancy. <i>Progress in Transplantation</i> , 2004, 14, 193-200.	0.7	20
130	Polyomavirus Nephropathy in Kidney Transplantation. <i>Progress in Transplantation</i> , 2004, 14, 130-142.	0.7	19
131	PAIRED EXCHANGES SHOULD BE PART OF THE SOLUTION TO ABO INCOMPATIBILITY IN LIVING DONOR KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 1998, 66, 406-407.	1.0	19
132	EARLY CORTICOSTEROID CESSATION AT ONE WEEK FOLLOWING KIDNEY TRANSPLANT UNDER TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESSION, THREE-YEAR FOLLOW-UP.. <i>Transplantation</i> , 2000, 69, S134.	1.0	18
133	Recurrence Risk After Organ Transplantation in Patients with a History of Hodgkin Disease or Non-Hodgkin Lymphoma. <i>Transplantation</i> , 2004, 78, 972-977.	1.0	18
134	Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells. <i>American Journal of Transplantation</i> , 2020, 20, 399-410.	4.7	18
135	Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 1691-1698.	4.7	18
136	Plasma cell targeting to prevent antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 33-41.	4.7	16
137	Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients. <i>JAMA Surgery</i> , 2021, 156, 307.	4.3	16
138	A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. <i>Clinical Transplantation</i> , 2018, 32, e13155.	1.6	15
139	A Prospective Trial of a Steroid-Free/Calcineurin Inhibitor Minimization Regimen in Human Leukocyte Antigen (HLA)-Identical Live Donor Renal Transplantation. <i>Transplantation</i> , 2009, 87, 408-414.	1.0	14
140	Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1951-1953.	6.1	14
141	IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 1692-1694.	27.0	14
142	Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3221-3230.	6.1	14
143	Early Steroid Withdrawal Does Not Increase Risk for Recurrent Focal Segmental Glomerulosclerosis. <i>Transplantation Proceedings</i> , 2005, 37, 817-818.	0.6	13
144	Management of Antibody-Mediated Rejection in Transplantation. <i>Surgical Clinics of North America</i> , 2013, 93, 1451-1466.	1.5	13

#	ARTICLE	IF	CITATIONS
145	Addressing the challenges of sleeve gastrectomy in end-stage renal disease: Analysis of 100 consecutive renal failure patients. <i>Surgery</i> , 2017, 162, 358-365.	1.9	13
146	mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28 ^{hi} Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. <i>Transplantation</i> , 2020, 104, 1058-1069.	1.0	13
147	Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1387-1397.	4.5	13
148	Incidental diagnosis of gastric cancer in transplant recipients improves patient survival. <i>Surgery</i> , 2002, 132, 754-760.	1.9	12
149	Clinical and investigational use of proteasome inhibitors for transplant rejection. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1535-1542.	4.1	12
150	Acute Rejection Characteristics From a Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Early Corticosteroid Withdrawal. <i>Transplantation</i> , 2013, 95, 573-579.	1.0	12
151	CLASS I MHC MEDIATES PROGRAMMED CELL DEATH IN HUMAN LYMPHOID CELLS ¹ . <i>Transplantation</i> , 1997, 64, 140-146.	1.0	12
152	One-Year Outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. <i>Kidney International Reports</i> , 2022, 7, 241-250.	0.8	12
153	Corticosteroid withdrawal in renal transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 247-248.	0.6	11
154	A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy. <i>Transplantation</i> , 2015, 99, 1691-1699.	1.0	10
155	Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes. <i>Progress in Transplantation</i> , 2016, 26, 183-190.	0.7	10
156	Laparoscopic Live Donor Nephrectomy: Rationale, Techniques, and Implications. <i>Seminars in Dialysis</i> , 2001, 14, 365-372.	1.3	9
157	Influence of Educational Programs on Perceived Barriers Toward Living Donor Kidney Exchange Programs. <i>Transplantation Proceedings</i> , 2005, 37, 602-604.	0.6	9
158	Kidney Transplantation: Graft Monitoring and Immunosuppression. <i>World Journal of Surgery</i> , 2002, 26, 185-193.	1.6	8
159	Early Corticosteroid Withdrawal Under Modern Immunosuppression in Renal Transplantation: Multivariate Analysis of Risk Factors for Acute Rejection. <i>Transplantation Proceedings</i> , 2005, 37, 798-799.	0.6	8
160	Histocompatibility Testing Predicts Acute Rejection Risk in Early Corticosteroid Withdrawal Regimens. <i>Transplantation Proceedings</i> , 2005, 37, 809-811.	0.6	8
161	Contrast-Induced Nephropathy in Renal Transplant Recipients: A Single Center Experience. <i>Frontiers in Medicine</i> , 2017, 4, 64.	2.6	8
162	Pilot Study of Early Corticosteroid Elimination After Pancreas Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1287-1288.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Bariatric surgery prior to living donor nephrectomy: a solution to expand the living donor kidney pool – a retrospective study. <i>Transplant International</i> , 2019, 32, 702-709.	1.6	7
164	United Network for Organ Sharing Publication on Scientific Registry of Transplant Recipients Central Nervous System Donor Cancer Transmission Data. <i>Transplantation</i> , 2005, 79, 623.	1.0	6
165	Steroid minimization for sirolimus-treated renal transplant recipients. <i>Clinical Transplantation</i> , 2011, 25, 457-467.	1.6	6
166	Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection. <i>Transplantation</i> , 2020, 104, 2403-2414.	1.0	6
167	Corticosteroid elimination in renal transplantation: pro. <i>Transplantation Proceedings</i> , 2002, 34, 1693.	0.6	5
168	Of Mice and Men: Terminal Complement Inhibition With Anti-C5 Monoclonal Antibodies. <i>American Journal of Transplantation</i> , 2011, 11, 2277-2278.	4.7	5
169	SARS-CoV-2 Vaccination, Immune Responses, and Antibody Testing in Immunosuppressed Populations: Tip of the Iceberg. <i>Transplantation</i> , 2021, 105, 1911-1913.	1.0	5
170	Advanced Genomics-Based Approaches for Defining Allograft Rejection With Single Cell Resolution. <i>Frontiers in Immunology</i> , 2021, 12, 750754.	4.8	5
171	Syndromic incidence of ovarian cancer after liver transplantation: Is breast cancer an antecedent risk?. <i>Liver Transplantation</i> , 2004, 10, 156-157.	2.4	4
172	Case Report: Hemolytic Anemia Following Deceased Donor Renal Transplantation Associated With Tranexamic Acid Administration for Disseminated Intravascular Coagulation. <i>Transplantation Proceedings</i> , 2015, 47, 2239-2242.	0.6	4
173	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. <i>PLoS ONE</i> , 2021, 16, e0254667.	2.5	4
174	Transplant-Related Malignancies. , 2005, , 1149-1164.		4
175	PROGRAMMED CELL DEATH SIGNALING VIA CELL-SURFACE EXPRESSION OF A SINGLE-CHAIN ANTIBODY TRANSGENE. <i>Transplantation</i> , 2000, 69, 1209-1217.	1.0	4
176	Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin. <i>Transplantation Proceedings</i> , 2015, 47, 2254-2257.	0.6	3
177	Plasma cell biology: Foundations for targeted therapeutic development in transplantation. <i>Immunological Reviews</i> , 2021, 303, 168-186.	6.0	3
178	Regulatory Approval for New Antihumoral Therapies: Addressing the Barriers. <i>American Journal of Transplantation</i> , 2011, 11, 880-881.	4.7	2
179	Corticosteroid elimination: the Cincinnati experience. <i>Clinical Transplants</i> , 2007, , 51-60.	0.2	2
180	A history of living donor transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 901-902.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Liver transplantation for primary and metastatic hepatic malignancy: a single center experience. Surgery, 2006, 139, 535-541.	1.9	1
182	Bortezomib-Based Antibody-Mediated Rejection Therapy and Simultaneous Conversion to Belatacept. Transplantation, 2014, 97, e30-e32.	1.0	1
183	SARS-CoV-2 Vaccination and Antibody Testing in Immunosuppressed Populations. Transplantation, 2021, Publish Ahead of Print, .	1.0	1
184	AFRICAN-AMERICAN PATIENTS WITH RENAL FAILURE SECONDARY TO DIABETES SHOULD BE REFERRED FOR COMBINED KIDNEY-PANCREAS TRANSPLANT. Transplantation, 1999, 67, S567.	1.0	1
185	Incorporating Patients's Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study. MDM Policy and Practice, 2021, 6, 238146832110565.	0.9	1
186	Hepatic perfusion abnormalities after liver transplantation. CardioVascular and Interventional Radiology, 1985, 8, 169-173.	2.0	0
187	DIETARY SUPPLEMENTATION WITH L-ARGININE AND CANOLA OIL REDUCES REJECTION EPISODES, RENAL BIOPSIES, REHOSPITALIZATION AND BLOOD PRESSURE FOLLOWING RENAL TRANSPLANTATION.. Transplantation, 2000, 69, S362.	1.0	0
188	Reply: Temporary abdominal coverage for adult liver transplantation. Liver Transplantation, 2007, 13, 1351-1352.	2.4	0
189	4-OR. Human Immunology, 2012, 73, 4.	2.4	0
190	Bortezomib Is a Successful Therapeutic Agent for Refractory Autoimmune Cytopenias in Children: A Single Center Experience. Biology of Blood and Marrow Transplantation, 2014, 20, S174.	2.0	0
191	Transplanting Hepatitis C Virus-Infected or Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients. Annals of Internal Medicine, 2018, 169, 898.	3.9	0
192	High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune Suppression. Current Transplantation Reports, 2019, 6, 60-68.	2.0	0
193	AB0167...SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCASIAN PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY. , 2019, , .		0
194	Treatment of large renal allograft arterial pseudoaneurysm with in situ cold perfusion, ex vivo vascular reconstruction and reimplantation. Journal of Nephropathology, 2019, 8, 10-10.	0.2	0